Watch the interview with the CEO Soren Bregenholt, in English, below.
Alligator Bioscience has exercised its warrant TO 12 during the period May 5 – 19. BioStock interviewed CEO Søren Bregenholt to gain deeper insight into the importance of the warrant program for the long-term financing strategy. He also shares how the company plans to differentiate itself in the current climate in the biotech sector.
Notes
AdaptVac awarded SEK 115 million for filovirus vaccine
Gilead receives FDA approval for long-acting HIV drug
Nanoform receives EUR 5 million loan from Business Finland
Alzinova presents promising antibody data
C-RAD signs agreement worth SEK 9 million
NEWSLETTER
NEWS
Alzinova's ALZ-101 normalizes protective antibody levels in Alzheimer's patients
Zealand Pharma reports promising results for dapiglutide
Curasight applies for clinical trial for uTREAT in brain cancer
Upcoming events!
Investing in Life Science
Join us in beautiful Stockholm as we focus on early-, growth- and late-stage investments in life science. From business angels...
Life Science Summit
The Nordic region's leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account
Chronicles
Trump is once again waving tariff threats – are they just empty words?
Bispecific and Chinese the new black in cancer
